---
schema_version: "secwatch.filing_event.v1"
accession: "0001682852-23-000033"
form_type: "8-K"
ticker: "MRNA"
cik: "0001682852"
company_name: "Moderna, Inc."
filed_at: "2023-10-16T23:59:59+00:00"
generated_at: "2026-06-09T23:25:49.734386+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Moderna reaffirms FY2023 COVID-19 vaccine revenue guidance of $6-8B; provides scenario-based range

## Summary
- Full-year 2023 COVID-19 vaccine revenue guidance unchanged at $6B-$8B.
- If U.S. market is ~50M doses, expects to be in bottom half of range.
- If U.S. market is ~100M doses, expects to be in top half of range.
- Too early to project; better visibility after October vaccination trends.
- Will provide an update at the November 2 earnings call.

## SEC filing metadata
- accession: 0001682852-23-000033
- form_type: 8-K
- ticker: MRNA
- cik: 0001682852
- company_name: Moderna, Inc.
- filed_at: 2023-10-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682852/000168285223000033/0001682852-23-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682852/000168285223000033/mrna-20231016.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001682852-23-000033
- JSON: https://secwatch.observer/filing/0001682852-23-000033.json
- Plain text: https://secwatch.observer/filing/0001682852-23-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.